IL326772A - מבני נוגדנים רב-ספציפיים אנטיil-13- ושימושים בהם - Google Patents

מבני נוגדנים רב-ספציפיים אנטיil-13- ושימושים בהם

Info

Publication number
IL326772A
IL326772A IL326772A IL32677226A IL326772A IL 326772 A IL326772 A IL 326772A IL 326772 A IL326772 A IL 326772A IL 32677226 A IL32677226 A IL 32677226A IL 326772 A IL326772 A IL 326772A
Authority
IL
Israel
Prior art keywords
multispecific antibody
antibody constructs
constructs
multispecific
antibody
Prior art date
Application number
IL326772A
Other languages
English (en)
Original Assignee
Proteologix Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologix Us Inc filed Critical Proteologix Us Inc
Publication of IL326772A publication Critical patent/IL326772A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL326772A 2023-08-25 2024-08-23 מבני נוגדנים רב-ספציפיים אנטיil-13- ושימושים בהם IL326772A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363578946P 2023-08-25 2023-08-25
PCT/US2024/043755 WO2025049345A1 (en) 2023-08-25 2024-08-23 Anti-il-13 multispecific antibody constructs and uses thereof

Publications (1)

Publication Number Publication Date
IL326772A true IL326772A (he) 2026-04-01

Family

ID=92800531

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326772A IL326772A (he) 2023-08-25 2024-08-23 מבני נוגדנים רב-ספציפיים אנטיil-13- ושימושים בהם

Country Status (6)

Country Link
AR (1) AR133647A1 (he)
AU (1) AU2024334289A1 (he)
CO (1) CO2026003590A2 (he)
IL (1) IL326772A (he)
TW (1) TW202525846A (he)
WO (1) WO2025049345A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025209486A1 (en) * 2024-04-02 2025-10-09 Keymed Biosciences (Chengdu) Co., Ltd. Antibodies targeting il-13 and tslp and uses thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL78444A (en) 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL88378A (en) 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
AU625866B2 (en) 1989-04-19 1992-07-16 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
US5959087A (en) 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
IL91562A0 (en) 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DK0695189T3 (da) 1992-12-29 1999-08-09 Genentech Inc Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer
US5888511A (en) 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US6350860B1 (en) 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
PL371773A1 (en) 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP1824886B1 (en) 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
PT1848744E (pt) 2005-01-27 2012-04-24 Novimmune Sa Anticorpos anti-interferão gama e os seus processos de utilização
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EA201170357A1 (ru) 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
PE20120835A1 (es) 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc Anticuerpos anti-tnf-alfa y sus usos
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
MX361242B (es) 2011-03-30 2018-11-30 Ablynx Nv Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
SG11201402490XA (en) 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
UA117608C2 (uk) 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
JP6832707B2 (ja) 2014-03-26 2021-02-24 セル メディカ スイッツァランド アーゲー ＴＮＦαに対する結合メンバー
KR20170123315A (ko) 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
HRP20210650T1 (hr) 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
US11136387B2 (en) 2016-05-18 2021-10-05 Shanghai Pharmaexplorer Co., Ltd. IL-13 antibody and preparation method and use thereof
PT3528838T (pt) 2016-09-23 2023-09-04 Hoffmann La Roche Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
KR102666879B1 (ko) 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
WO2019154420A1 (zh) 2018-02-12 2019-08-15 上海原能细胞医学技术有限公司 Il17抗体及其应用
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
JP7628966B2 (ja) 2019-06-04 2025-02-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド 胸線間質性リンパ球増殖因子に結合可能な抗体およびその使用
AU2020323901A1 (en) * 2019-07-26 2022-02-24 Amgen Inc. Anti-IL13 antigen binding proteins
EP4025602A4 (en) 2019-09-04 2023-12-13 Biosion, Inc. TSLP BINDING ANTIBODIES AND USES THEREOF
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
CN114887053B (zh) 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
AR120698A1 (es) * 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
MX2022007035A (es) 2019-12-09 2022-06-23 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp.
US20240101675A1 (en) 2021-01-21 2024-03-28 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
US20250277022A1 (en) 2021-02-04 2025-09-04 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
IL308360A (he) 2021-05-30 2024-01-01 Biolojic Design Ltd נוגדנים מהונדסים בעלי קשירה דואלית ושימושיהם
CN117642423A (zh) 2021-09-13 2024-03-01 深圳华普药物研发有限公司 一种il17抗体及其制备方法和应用
CN117209603B (zh) 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Also Published As

Publication number Publication date
TW202525846A (zh) 2025-07-01
AR133647A1 (es) 2025-10-22
AU2024334289A1 (en) 2026-04-09
CO2026003590A2 (es) 2026-04-06
WO2025049345A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
IL315265A (he) נוגדנים מרובים ושימושים בהם
GB202017058D0 (en) Antibodies and uses thereof
IL319931A (he) נוגדנים אנטי- cd122 ושימושים בהם
IL299865A (he) קולטני אנטיגן כימריים רב-ספציפיים ושימושים בהם
PL3932949T3 (pl) Przeciwciało anty-cd25 i jego zastosowanie
EP4217389A4 (en) ANTI-SCLEROSTIN CONSTRUCTS AND USES THEREOF
ZA202208799B (en) Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
SG11202107995SA (en) Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
IL320586A (he) נוגדן נגד trem2 ושימושים שלו
IL326772A (he) מבני נוגדנים רב-ספציפיים אנטיil-13- ושימושים בהם
EP4464722A4 (en) ANTIBODIES AND THEIR USE
EP4640711A4 (en) HIGH-AFFINITY ANTI-TIGIT ANTIBODY AND ITS USE
IL316510A (he) נוגדן אנטי-b7h3 ושימושיו
EP4437000A4 (en) ANTI-TREM2 ANTIBODY AND ITS USES
IL320972A (he) נוגדנים אנטי-tfr1 ושימושים בהם
IL315541A (he) נוגדנים רב-ספציפיים ושימושים בהם
IL315540A (he) נוגדנים רב-ספציפיים ושימושים בהם
CA3302539A1 (en) Anti-il-13 multispecific antibody constructs and uses thereof
EP4003421A4 (en) CONSTRUCTIONS OF MULTIVALENT DNA ANTIBODIES AND THEIR USE
GB202303531D0 (en) Antibodies and uses thereof
EP4493597A4 (en) Masp-2-targetting antibodies and uses thereof
IL325822A (he) נוגדנים רב-ספציפיים ושימושים בהם
IL315544A (he) נוגדנים רב-ספציפיים ושימושים בהם
IL326774A (he) מבני נוגדנים אנטיtslp- ושימושים בהם
HK40116351A (en) Multispecific antibody and use thereof